Preliminary Findings on the Use of Targeted Therapy with Pazopanib and Other Agents in Combination with Sodium Phenylbutyrate in the Treatment of Glioblastoma Multiforme
Read full paper at: http://www.scirp.org/journal/PaperInformation.aspx?PaperID=52600#.VJyu-cCAM4 Author(s) Stanislaw R. Burzynski * , Tomasz J. Janicki , Gregory S. Burzynski , Sheldon Brookman Affiliation(s) Burzynski Clinic, Houston, USA . ABSTRACT The most common and aggressive type of brain tumor is glioblastoma multiforme (GBM). The prognosis for GBM remains poor with a five-year survival rate between 1% and 2%. The prospects for patients with recurrent GBM (RGBM) are much worse, with the majority dying within 6 months. This publication provides a brief description of the treatment of 11 GBM patients treated with sodium phenylbutyrate (PB) in combination with pazopanib, m-TOR inhibi...